Antev Asset Acquisition (Tables)

12 Months Ended

Dec. 31, 2025

Antev Asset Agreement [Abstract]

Schedule of contingent consideration [Table Text Block]

Phases	Contingent Consideration agreed for Antev shares acquired through issue of shares	Contingent Consideration agreed for Antev shares acquired by cash payment
(i) Advanced Prostate Cancer - Phase 2 success or registration	$2.00 per common share issued	$1.47 per Antev share (pro rata interest in $5,333,200)
(ii) Acute Urinary Retention Prevention - Phase 2 success or registration	$7.50 per common share issued	$5.52 per Antev share (pro rata interest in $19,999,500)
(iii) FDA NDA approval - Hormone therapy for prostate cancer	Up to $20,000,000 (subject to pro rata reduction)	$5.52 per Antev share (pro rata interest in $20,000,000
(iv) FDA NDA approval - AUR prevention	Up to $20,000,000 (subject to pro rata reduction)	$5.52 per Antev share (pro rata interest in $20,000,000)

Schedule of consideration paid [Table Text Block]

Fair value of 1,603,164 common shares	$	2,443,344
Cash paid		2,970,166
Transaction expenses		1,992,798
Contingent consideration		-
Total fair value consideration		7,406,308
Fair value of non-controlling interest		105,161
Total fair value for allocation to net assets of Antev		7,511,469

Schedule of assets acquired [Table Text Block]

Cash	$	13,353
Assets		224,719
Accrued and other accounts payable		(1,327,429	)
Other liabilities		(116,649	)
IPR&D - Teverelix		8,717,475
Net assets acquired	$	7,511,469